Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

Allergan3,423 enrolled

Overview

This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.

Study Type

OBSERVATIONAL

Enrollment

3,423

Conditions

Conjunctivitis, Allergic

Interventions

Alcaftadine Ophthalmic Solution 0.25%DRUG

Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.

Eligibility

Sex: ALLMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: -Patients with itching associated with allergic conjunctivitis. Exclusion Criteria: -Patients with hypersensitivity to Lastacaft® or its components.

Locations (81)

Outcomes

Primary Outcomes

Number of Participants with Adverse Events

Time frame: 2 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Seo-myeon St.Mary's Hospital

Busan, South Korea

SeoMyeon St. Eye Clinic

Busan, South Korea

Inje University Busan Paik Hospital

Busan, South Korea

Soojung Eye Hospital

Busan, South Korea

Inje University Haeundae Paik Hospital

Busan, South Korea

Saint Mary Bright Eye Clinic

Busan, South Korea

Daeyeon St.mary's Eye Center

Busan, South Korea

Dong-A University Hospital

Busan, South Korea

Pusan National University Hospital

Busan, South Korea

Pusan National University Yangsan Hospital

Busan, South Korea

...and 71 more locations